DexCom (DXCM) Stock Price, News & Analysis

Company Overview

DexCom, Inc. is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations. The company’s product portfolio includes commercially marketed systems—most notably its G6 and G7 families—which are intended to simplify sensor insertion, extend wearable life and improve ease of use. These systems are used in both personal and professional settings, including by patients at home and by clinicians who monitor glucose remotely.

DexCom’s CGM ecosystem emphasizes connectivity and interoperability. Its devices support mobile apps for real-time glucose display and data sharing with caregivers, and are designed to integrate with insulin delivery systems and other digital health platforms to enable automated or guided diabetes management workflows. The company also invests in software and data analytics to enhance actionable insights for users and providers.

Operating commercially in the United States and across multiple international markets, including Europe and parts of the Asia‑Pacific region, DexCom pursues expanded access through reimbursement initiatives, partnerships and regulatory approvals. The company has emphasized ongoing research and development aimed at improving sensor accuracy, user convenience and the broader clinical applications of continuous glucose monitoring. It is led by CEO Kevin Sayer and a management team focused on device innovation and global commercial growth.

Key Stats

• Today's Range: $58.98 to $61.00
• 50-Day Range: $57.56 to $74.38
• 52-Week Range: $54.11 to $89.98
• Volume: 5.53 million shs
• Average Volume: 4.92 million shs
• Market Capitalization: $22.95 billion
• P/E Ratio: 25.42
• Dividend Yield: N/A
• Price Target: $83.50
• Consensus Rating: Moderate Buy

DexCom Stock Analysis - MarketRank™

DexCom scored higher than 94% of companies evaluated by MarketBeat, and ranked 40th out of 854 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

DexCom has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 2 strong buy ratings, 18 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

DexCom has a consensus price target of $83.50, representing about 41.0% upside from its current price of $59.23.

Amount of Analyst Coverage

DexCom has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 18.25%

Earnings Growth

Earnings for DexCom are expected to grow by 18.25% in the coming year, from $2.52 to $2.98 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of DexCom is 25.33, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.55.

Price to Earnings Ratio vs. Sector

The P/E ratio of DexCom is 25.33, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.06.

Price to Earnings Growth Ratio

DexCom has a PEG Ratio of 1.18. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

DexCom has a P/B Ratio of 8.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.95% of the float of DexCom has been sold short.

Short Interest Ratio / Days to Cover

DexCom has a short interest ratio ("days to cover") of 4.06.

Change versus previous month

Short interest in DexCom has recently increased by 3.22%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

DexCom does not currently pay a dividend.

Dividend Growth

DexCom does not have a long track record of dividend growth.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 0.70

News Sentiment

DexCom has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 41 news articles for DexCom this week, compared to 12 articles on an average week.

Search Interest

17 people have searched for DXCM on MarketBeat in the last 30 days. This is an increase of 31% compared to the previous 30 days.

MarketBeat Follows

10 people have added DexCom to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, DexCom insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $217,413.00 in company stock.

Percentage Held by Insiders

0.28% of the stock of DexCom is held by insiders.

Percentage Held by Institutions

97.75% of the stock of DexCom is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DXCM Stock Analysis - Frequently Asked Questions

How have DXCM shares performed this year?

DexCom's stock was trading at $66.37 at the start of the year. Since then, DXCM stock has decreased by 10.8% and is now trading at $59.2310.

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) posted its quarterly earnings results on Thursday, April, 30th. The medical device company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.47 by $0.09. The business's revenue was up 15.0% compared to the same quarter last year.
Read the conference call transcript.

When did DexCom's stock split?

DexCom's stock split before market open on Friday, June 10th 2022.The 4-1 split was announced on Friday, March 25th 2022. The newly created shares were payable to shareholders after the closing bell on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

Does DexCom have any subsidiaries?

DexCom subsidiaries include TypeZero Technologies Inc, Nintamed Handels GmbH, DexCapital LLC, DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom (Canada) Inc., DexCom Deutschland GmbH, and others.

Who are DexCom's major shareholders?

DexCom's top institutional shareholders include SG Americas Securities LLC (0.54%), DSM Capital Partners LLC (0.50%), Assenagon Asset Management S.A. (0.45%) and Stephens Investment Management Group LLC (0.28%). Insiders that own company stock include Kevin R Sayer, Jacob Steven Leach, Jereme M Sylvain, Steven Robert Pacelli, Michael Jon Brown, Sadie Stern, Barry J Regan, Steven R Altman, Mark G Foletta, Shelly Ramasamy Selvaraj, Matthew Vincent Dolan, Richard Alexander Collins, Nicholas Augustinos, Bridgette P Heller and Kyle Malady.
View institutional ownership trends.

How do I buy shares of DexCom?

Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of DexCom own?

Based on aggregate information from My MarketBeat watchlists, some other companies that DexCom investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Invesco QQQ (QQQ).

Company Calendar

• Last Earnings: 4/30/2026
• Today: 5/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:DXCM
• CIK: 1093557
• Web: www.dexcom.com
• Phone: (858) 200-0200
• Fax: 858-200-0201
• Employees: 11,000
• Year Founded: 1999

Price Target and Rating

• Average Price Target for DexCom: $83.50
• High Price Target: $102.00
• Low Price Target: $67.00
• Potential Upside/Downside: +40.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 24 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.34
• Trailing P/E Ratio: 25.43
• Forward P/E Ratio: 23.62
• P/E Growth: 1.18
• Net Income: $836.30 million
• Net Margins: 19.31%
• Pretax Margin: 24.98%
• Return on Equity: 33.33%
• Return on Assets: 13.19%

Debt

• Debt-to-Equity Ratio: 0.42
• Current Ratio: 1.95
• Quick Ratio: 1.64

Sales & Book Value

• Annual Sales: $4.66 billion
• Price / Sales: 4.93
• Cash Flow: $2.69 per share
• Price / Cash Flow: 22.16
• Book Value: $7.04 per share
• Price / Book: 8.45

Miscellaneous

• Outstanding Shares: 385,870,000
• Free Float: 384,793,000
• Market Cap: $22.96 billion
• Optionable: Optionable
• Beta: 1.40